Systemic adjuvant therapies in renal cell carcinoma

Systemic adjuvant therapies in renal cell carcinoma

Renal cell carcinoma (RCC) is one of the ten most frequent solid tumors worldwide. Recent innovations in the treatment of metastatic disease have led to new therapeutic approaches being investigated in the adjuvant setting. Observation is the only current standard of care after radical nephrectomy, although there is evidence of efficacy of adjuvant use of vaccine among all the strategies used. ...

Adjuvant systemic therapies in breast cancer.

Although some women with early breast cancer (BC) may be cured with loco-regional treatment alone, up to 20% of patients with early-stage BC will ultimately experience treatment failure and recurrence. A substantial portion of the success in improving clinical outcomes of patients with BC is related to the standardized use of adjuvant therapies. The identification of tumor subtypes with prognos...

Renal-cell carcinoma--molecular pathways and therapies.

n engl j med 356;2 www.nejm.org january 11, 2007 185 We urge investigators, including those who receive funding from the National Institutes of Health or other nonindustry sources, to ensure that the studies they conduct are registered with complete information and to check the registration records for accuracy. Specific information about how to register a study in ClinicalTrials.gov can be fou...

Systemic therapy for advanced renal cell carcinoma.

Renal cell carcinoma (RCC) accounts for approximately 3% of all cancers and is refractory to cytotoxic chemotherapy - immunotherapy has until recently been the standard of care for advanced disease. Randomised trials reported in the last 5 years have demonstrated that a number of agents including the monoclonal antibody, bevacizumab, and the kinase inhibitors - sorafenib sunitinib, temsirolimus...

Sarcomatoid Transrormation of Chromophobe Renal Cell Carcinoma